A Research Study Examining the Use of Olanzapine for the Prevention of Migraine
Status:
Terminated
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug
Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar
disorder. The trade name for this drug is Zyprexa®. Olanzapine has not been approved by the
FDA for the prevention of migraine and is experimental for the purposes of this research
study.
The Jefferson Headache Center at Thomas Jefferson University has developed this clinical
study to evaluate the safety and effectiveness of Olanzapine in preventing migraine
headaches.